# Behavioral Neurology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Law Olmsted (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI022-SYN-TD
- Date: 1895-06-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Nathan Calder, MD

## Reason for consultation

Progressive memory loss over about two years in a 73-year-old landscape architect who has had to step back from his practice. Please confirm whether this is dementia or mild cognitive impairment, advise on the likely type and on biomarker testing, advise on treatment, and advise on driving. **S**

## History

Mr. Olmsted, a 73-year-old landscape architect, is seen with his caregiver at the request of Dr. Calder for about two years of progressive memory loss. He repeats questions, loses track of correspondence and plans, and needs reminders for appointments; he stepped back from his practice this year. His caregiver now manages his medicines and bill paying. He drives short familiar routes and took a wrong turn near home this month. He has no visual hallucinations, fluctuations in alertness, acting out of dreams, tremor, falls, gait change, urinary incontinence, change in personality or social conduct, or difficulty finding words beyond names. He is irritable and apathetic at times and sad about leaving his work, without thoughts of self-harm. He stopped his glass of wine with dinner a month ago and takes no medicines. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert, courteous, and articulate; repeats one question during the visit |
| Cognition | Oriented to person and place, not to date; recalls 1 of 3 words after five minutes, helped partly by cues; reduced letter fluency; clock drawing with misplaced numbers; naming, repetition, and comprehension intact; no neglect or apraxia |
| Mood and behavior | Mildly flat; appropriate and socially engaged; no disinhibition |
| Cranial nerves | Full eye movements, including vertical gaze; face symmetric |
| Motor | Normal tone; no rest tremor, rigidity, or bradykinesia; strength normal |
| Reflexes and sensation | Reflexes symmetric; plantar responses flexor; no primitive reflexes; sensation intact |
| Gait | Normal stride, base, and arm swing; no magnetic or shuffling quality; turns steadily |

BP 132/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 71.8 kg; BMI 23.4 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Calder's assessment four weeks ago: MoCA 19 with its item profile, Katz ADL, Lawton IADL, NPI-Q, PHQ-9 6, and Timed Up and Go; blood count, metabolic panel, albumin, ALT, vitamin B12, folate, and TSH, all normal; the brain MRI images and report from two weeks ago; and today's pulse and blood pressure. 

## Assessment

1. **Mild dementia, type undetermined** (F03.A0). Mild dementia (CDR global 1, FAST stage 4) rather than mild cognitive impairment, because his loss of independence in finances, medicines, and planning reflects cognitive decline. The tests have excluded thyroid disease, vitamin B12 and folate deficiency, and metabolic causes, and the MRI excludes stroke, tumor, subdural hematoma, and hydrocephalus. **S**
2. **Type of dementia**. The gradual amnestic onset with executive difficulty and mild medial temporal atrophy fits Alzheimer's disease best, but the atrophy is within the range seen in some older adults without it, and mixed causes are common at his age. The small-vessel change is too slight to explain dementia. There are no core features of dementia with Lewy bodies, no behavioral or language features of frontotemporal dementia, and no gait or urinary features of normal pressure hydrocephalus. Without biomarkers the type cannot be established, and it is recorded as undetermined. **S**
3. **Biomarkers and anti-amyloid therapy**. A blood p-tau217 test, CSF, or amyloid PET could show whether Alzheimer's pathology is present, and with mild dementia he could be assessed for anti-amyloid therapy after APOE genotyping. After discussion he does not want infusions with repeated MRI monitoring and their risk of brain swelling or bleeding, and the result would not change the rest of his care. He and his caregiver chose not to test now; the option remains open. **S**
4. **Cholinesterase inhibitor**. With Alzheimer's disease the most likely cause, a trial of donepezil is reasonable. His pulse is 70 with no fainting or conduction symptoms, so no ECG is needed first. **S**
5. **Driving and safety**. At CDR 1 with a recent wrong turn, his crash risk is high, and stopping driving is advised over an on-road test. There are no firearms at home. He has not wandered. **S**

## Recommendations

1. Start donepezil 5 mg each morning, and increase to 10 mg after four to eight weeks if tolerated; check pulse, fainting, nausea, diarrhea, weight, and sleep at each visit.
2. Avoid anticholinergic and sedating drugs: diphenhydramine and other first-generation antihistamines, over-the-counter PM sleep aids, bladder antispasmodics, benzodiazepines, and sleeping pills.
3. Stop driving now; he agreed today.
4. Keep the home free of firearms; wear a medical identification bracelet; caregiver to supervise medicines and oversee finances; home safety checklist.
5. No biomarker testing or anti-amyloid therapy now, by his choice; revisit if his wishes change.
6. No repeat imaging or further laboratory tests unless the course becomes rapid or atypical; no syphilis or HIV testing without risk factors.
7. Caregiver support: Zarit Burden Interview, education, adult day program and respite, and the Alzheimer's Association helpline.
8. Advance care planning soon, while he can take full part.
9. Primary care reviews every three months for the first year on the CMID schedule, with MoCA, ADL and IADL, and CDR stage yearly.

## Strengths and supports

- Supports: his primary caregiver, family at home, long-time colleagues who visit, and a lifelong love of gardens and walking **S**

## Communication

Discussed with Dr. Calder, who sees him the same day. The diagnosis, its uncertainty, and the plan were explained plainly to Mr. Olmsted, as he asked, and to his caregiver; he agreed to the plan and to stop driving. **S**

## Follow-up

Behavioral neurology review in one year, or sooner for a faster decline, hallucinations, fluctuations, falls, or new behavioral symptoms. **S**

## Guideline basis

- Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001), American Academy of Neurology (Neurology)
- Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010), American Academy of Neurology (Neurology)
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2025), Alzheimer's Association (Alzheimer's & Dementia)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026), Aether Forge
